Effect of prebiotic and probiotic supplementation on circulating pro-inflammatory cytokines and urinary cortisol levels in patients with major depressive disorder: A double-blind, placebo-controlled randomized clinical trial

Kazemi, Asma; Noorbala, Ahmad Ali; Azam, Kamal; Djafarian, Kurosh

doi:10.1016/j.jff.2018.11.041

Cited by 45 publications

(67 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A potential connection between abnormal immune response, food-derived compounds, and MDD is still poorly understood; however, increasing evidence has confirmed the importance of the interplay between microbiota, gut permeability, immune-inflammatory processes in the pathophysiology of MDD [83]. The modulation of the gut-microbiota-brain axis could therefore be a promising therapeutic target for mental illnesses [15, 16, 84]. This concept has produced a new clinical approach involving dietary interventions restoring gut eubiosis in the treatment of MDD.…”

Section: Discussionmentioning

confidence: 99%

The study evaluating the effect of probiotic supplementation on the mental status, inflammation, and intestinal barrier in major depressive disorder patients using gluten-free or gluten-containing diet (SANGUT study): a 12-week, randomized, double-blind, and placebo-controlled clinical study protocol

Karakuła-Juchnowicz

Róg

Juchnowicz

et al. 2019

Nutr J

View full text Add to dashboard Cite

Background Current treatment of major depressive disorder (MDD) often does not achieve full remission of symptoms. Therefore, new forms of treatment and/or adjunct therapy are needed. Evidence has confirmed the modulation of the gut–brain–microbiota axis as a promising approach in MDD patients. The overall purpose of the SANGUT study—a 12-week, randomized, double-blind, and placebo-controlled Study Evaluating the Effect of Probiotic Supplementation on the Mental Status, Inflammation, and Intestinal Barrier in Major Depressive Disorder Patients Using Gluten-free or Gluten-containing Diet — is to determine the effect of interventions focused on the gut-brain-microbiota axis in a group of MDD patients. Methods A total of 120 outpatients will be equally allocated into one of four groups: (1) probiotic supplementation+gluten-free diet group (PRO-GFD), (2) placebo supplementation+ gluten-free diet group (PLA-GFD), (3) probiotic supplementation+ gluten containing diet group (PRO-GD), and (4) placebo supplementation+gluten containing diet group (PLA-GD). PRO groups will receive a mixture of psychobiotics ( Lactobacillus helveticus R0052 and Bifidobacterium longum R0175), and GFD groups will follow a gluten-free diet. The intervention will last 12 weeks. The primary outcome measure is change in wellbeing, whereas the secondary outcome measures include physiological parameters. Discussion Microbiota and its metabolites have the potential to influence CNS function. Probiotics may restore the eubiosis within the gut while a gluten-free diet, via changes in the microbiota profile and modulation of intestinal permeability, may alter the activity of microbiota-gut-brain axis previously found to be associated with the pathophysiology of depression. It is also noteworthy that microbiota being able to digest gluten may play a role in formation of peptides with different immunogenic capacities. Thus, the combination of a gluten-free diet and probiotic supplementation may inhibit the immune-inflammatory cascade in MDD course and improve both psychiatric and gut barrier-associated traits. Trial registration NCT03877393 .

show abstract

Section: Discussionmentioning

confidence: 99%

The study evaluating the effect of probiotic supplementation on the mental status, inflammation, and intestinal barrier in major depressive disorder patients using gluten-free or gluten-containing diet (SANGUT study): a 12-week, randomized, double-blind, and placebo-controlled clinical study protocol

Karakuła-Juchnowicz

Róg

Juchnowicz

et al. 2019

Nutr J

View full text Add to dashboard Cite

show abstract

“…Lactobacillus helveticus intake enabled the recovery of chronicand subchronic-stressed rodents from their state of depression (Liang et al, 2015;Maehata et al, 2019). Probiotic sticks containing L. helveticus, in addition to Bifidobacterium longum, reduced clinical depression and depressive-like symptoms in MDD patients (Kazemi et al, 2019) and healthy individuals (Messaoudi et al, 2011), respectively. Most of the animal and human studies also showed that L. helveticus intake enhanced memory and, sometimes, attention and learning (Ohland et al, 2013;Chung et al, 2014;Luo et al, 2014;Liang et al, 2015;Ohsawa et al, 2018).…”

Section: Lactobacillus Helveticusmentioning

confidence: 99%

“…A pilot study showed that MSP, together with a magnesium supplement, decreased depression in SSRI treatment-resistant patients (Bambling et al, 2017). A clinical trial also reported that the combination of B. longum and L. helveticus decreased depression in MDD patients with prior use of standard antidepressants (Kazemi et al, 2019).…”

Section: Heterogeneity Of Depressionmentioning

confidence: 99%

“…However, MSPs may have higher potency in humans. In MDD patients, SSP (L. plantarum) did not reduce depression but improved cognition (Lew et al, 2018), whereas MSPs had repeatedly shown antidepressive efficacy (Akkasheh et al, 2016;Bambling et al, 2017;Ghorbani et al, 2018;Kazemi et al, 2019). MSPs often gave better therapeutic efficacy compared to that of SSPs in gut-related disorders and pathogen infections, which could be explained by an overall higher dosage (Chapman et al, 2011(Chapman et al, , 2012.…”

Section: Single-species and Multi-species Probioticmentioning

confidence: 99%

See 1 more Smart Citation

Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential

et al. 2020

View full text Add to dashboard Cite

The accumulating knowledge of the host-microbiota interplay gives rise to the microbiota-gut-brain (MGB) axis. The MGB axis depicts the interkingdom communication between the gut microbiota and the brain. This communication process involves the endocrine, immune and neurotransmitters systems. Dysfunction of these systems, along with the presence of gut dysbiosis, have been detected among clinically depressed patients. This implicates the involvement of a maladaptive MGB axis in the pathophysiology of depression. Depression refers to symptoms that characterize major depressive disorder (MDD), a mood disorder with a disease burden that rivals that of heart diseases. The use of probiotics to treat depression has gained attention in recent years, as evidenced by increasing numbers of animal and human studies that have supported the antidepressive efficacy of probiotics. Physiological changes observed in these studies allow for the elucidation of probiotics antidepressive mechanisms, which ultimately aim to restore proper functioning of the MGB axis. However, the understanding of mechanisms does not yet complete the endeavor in applying probiotics to treat MDD. Other challenges remain which include the heterogeneous nature of both the gut microbiota composition and depressive symptoms in the clinical setting. Nevertheless, probiotics offer some advantages over standard pharmaceutical antidepressants, in terms of residual symptoms, side effects and stigma involved. This review outlines antidepressive mechanisms of probiotics based on the currently available literature and discusses therapeutic potentials of probiotics for depression.

show abstract

“…In patients with major depressive disorder (MDD), probiotics treatment (≥10 × 10 9 CFU of freeze-dried Helveticus R0052 and B. longum R0175 bacteria) for 8 weeks improved depression symptoms, but the serum inflammatory cytokines marker (TNF-α, IL-1β, IL-6, and IL-10) levels were not improved, and the urinary cortisol levels decreased by 20% of baseline. However, the prebiotics treatment (galactooligosaccharides, GOS) had no effect on depression symptoms nor inflammatory marker levels [110]. In a like manner, oral GOS administration reduced the human stress hormone cortisol and increased attentional vigilance to positive versus negative stimuli [111].…”

Section: Potential Effects On Microbiota-galt-brain Axismentioning

confidence: 95%

Prebiotics and the Modulation on the Microbiota-GALT-Brain Axis

Franco‐Robles¹,

Ramı́rez-Emiliano²,

López-Briones³

et al. 2020

Prebiotics and Probiotics - Potential Benefits in Nutrition and Health

View full text Add to dashboard Cite

It is well known that there exists a bi-directional communication system between the enteric nervous system and central nervous system. Recent research has attempted to understand the influence of intestinal bacteria on the brain and behavior. In this manner, it has been observed that pathogenic bacterial products such as lipopolysaccharides (LPSs) can induce behavioral changes such as acute anxiety, depressive symptoms, cognitive deficits, and increased sensitivity to visceral pain. The modulation of LPS production through probiotics, prebiotics, and symbiotics can prevent these changes. In addition to the neuronal, endocrine, and metabolic pathways, it has been observed that the immune mechanism also exerts an influence on the gut-brain axis. The cells of the immune system can undergo phenotypic changes by the induction of certain bacterial species, which can have an important participation in the development of brain disorders. Although the main effect of prebiotics is through the stimulation of probiotic bacteria, in this chapter, we review the indirect therapeutic potential of prebiotics on the brain through the intestinal microbiota, the gut-associated lymphoid tissue (GALT), and other components of the intestinal lumen. Thus, the objective is to elucidate the mechanisms underlying its effects on the gut-brain axis. Here, we will summarize the possible therapeutic effect of prebiotics on intestinal microbiota, the gut-associated lymphoid tissue (GALT), and brain.

show abstract

Effect of prebiotic and probiotic supplementation on circulating pro-inflammatory cytokines and urinary cortisol levels in patients with major depressive disorder: A double-blind, placebo-controlled randomized clinical trial

Cited by 45 publications

References 42 publications

Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential

Prebiotics and the Modulation on the Microbiota-GALT-Brain Axis

Contact Info

Product

Resources

About